help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SULLIVAN, J. H.
Right arrow Articles by CHAISSON, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SULLIVAN, J. H.
Right arrow Articles by CHAISSON, R. E.

Am. J. Respir. Crit. Care Med., Volume 162, Number 1, July 2000, 64-67

Effect of Antiretroviral Therapy on the Incidence of Bacterial Pneumonia in Patients with Advanced HIV Infection

JEFFREY H. SULLIVAN, RICHARD D. MOORE, JEANNE C. KERULY, and RICHARD E. CHAISSON

Johns Hopkins School of Medicine, Baltimore, Maryland

To determine the relationship of combination antiretroviral therapy and bacterial pneumonia, we assessed incidence of and risk factors for bacterial pneumonia in 1,898 human immunodeficiency virus (HIV)-infected patients with CD4 cell counts < 200/mm3 followed in the Johns Hopkins HIV clinic between 1993 and 1998. A total of 352 episodes of bacterial pneumonia occurred during 2,310 patient-years of follow-up. Incidence of bacterial pneumonia decreased from 22.7 episodes/100 person-years (py) in the first half of 1993 to 12.3 episodes/100 py in the first half of 1996, reaching a nadir of 9.1 episodes/100 py in the second half of 1997 (p < 0.05). The use of protease inhibitor-containing regimens was associated with a decreased risk of bacterial pneumonia (risk ratio [RR] 0.55, 95% CI 0.31 to 0.94). Lower CD4 cell counts (RR 2.22, 95% CI 1.54 to 3.18), injection drug use as HIV transmission category (RR2.0, 95% CI 1.43 to 2.76), and prior Pneumocystis carinii pneumonia (RR 3.88, 95% CI 1.65 to 9.16) were also significantly associated with bacterial pneumonia. Trimethoprim-sulfamethoxazole and macrolide use were not significantly associated with risk of bacterial pneumonia. There has been a dramatic decline in the incidence of bacterial pneumonia resulting from the use of combination antiretroviral therapy containing protease inhibitors.




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
I. Kousignian, O. Launay, C. Mayaud, C. Rabaud, D. Costagliola, S. Abgrall, and on behalf of the FHDH-ANRS CO4
Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?
J. Antimicrob. Chemother., November 10, 2009; (2009) dkp402v1.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. W. Hull, P. Phillips, and J. S. G. Montaner
Changing Global Epidemiology of Pulmonary Manifestations of HIV/AIDS
Chest, December 1, 2008; 134(6): 1287 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. M. Gordin, M. P. Roediger, P.-M. Girard, J. D. Lundgren, J. M. Miro, A. Palfreeman, M. C. Rodriguez-Barradas, M. J. Wolff, P. J. Easterbrook, K. Clezy, et al.
Pneumonia in HIV-infected Persons: Increased Risk with Cigarette Smoking and Treatment Interruption
Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 630 - 636.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
C. Steele, L. Marrero, S. Swain, A. G. Harmsen, M. Zheng, G. D. Brown, S. Gordon, J. E. Shellito, and J. K. Kolls
Alveolar Macrophage-mediated Killing of Pneumocystis carinii f. sp. muris Involves Molecular Recognition by the Dectin-1 {beta}-Glucan Receptor
J. Exp. Med., December 1, 2003; 198(11): 1677 - 1688.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S H Allen, P Brennan-Benson, M Nelson, D Asboe, M Bower, B Azadian, B Gazzard, and J Stebbing
Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era
Postgrad. Med. J., December 1, 2003; 79(938): 691 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
C. W. Brecher, G. Aviram, and P. M. Boiselle
CT and Radiography of Bacterial Respiratory Infections in AIDS Patients
Am. J. Roentgenol., May 1, 2003; 180(5): 1203 - 1209.
[Full Text] [PDF]

Home page
 ChestHome page
K. M. O'Neil
The Changing Landscape of HIV-Related Lung Disease in the Era of Highly Active Antiretroviral Therapy
Chest, September 1, 2002; 122(3): 768 - 771.
[Full Text] [PDF]

Home page
 ChestHome page
A. J. Wolff and A. E. O'Donnell
Pulmonary Manifestations of HIV Infection in the Era of Highly Active Antiretroviral Therapy
Chest, December 1, 2001; 120(6): 1888 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788.
[Full Text] [PDF]

Home page
 JWatch Infect. DiseasesHome page
Antiretroviral Therapy Reduces Risk for Bacterial Pneumonia
Journal Watch Infectious Diseases, August 24, 2000; 2000(824): 11 - 11.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  2nd Annual Dinner